Heparin dosing in obese pediatric patients in the cardiac catheterization laboratory;Administración de heparina en pacientes pediátricos obesos en el laboratorio de cateterismo cardiaco

Annals of Pharmacotherapy

Volumn 45, Issue 7-8, 2011, Pages 876-880

  Moffett, Brady S ^a   Teruya, Jun ^b   Petit, Christopher ^b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiac catheterization; Obesity; Pediatrics

Indexed keywords

HEPARIN;

ACTIVATED BLOOD CLOTTING TIME; ADOLESCENT; ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TIME; BODY MASS; BODY WEIGHT; CHILD; CONTROLLED STUDY; DEMOGRAPHY; DRUG MEGADOSE; FEMALE; HEART CATHETERIZATION; HUMAN; LABORATORY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOLECULAR WEIGHT; OBESITY; PEDIATRIC HOSPITAL; PEDIATRICS; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ANTICOAGULANTS; BLOOD COAGULATION; BODY MASS INDEX; BODY WEIGHT; CASE-CONTROL STUDIES; CATHETER ABLATION; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART CATHETERIZATION; HEPARIN; HUMANS; MALE; MEDICAL RECORDS; OBESITY; RETROSPECTIVE STUDIES; WHOLE BLOOD COAGULATION TIME;

EID: 79960774512     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q090     Document Type: Article

References (20)

1. Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003-2006. JAMA 2008;299:2401-2405.
2. Centers for Disease Control and Prevention. About BMI for children and teens. http://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html (accessed 2011 Jan 1).
3. Choi JJ, Moffett BS, McDade EJ, Palazzi DL. Altered gentamicin serum concentrations in obese pediatric patients. Pediatr Infect Dis J 2011;30: 347-349.
4. Estes JW. Clinical pharmacokinetics of heparin. Clin Pharmacokinet 1980;5:204-220.
5. Riney JN, Hollands JM, Smith JR, Deal EN. Identifying optimal initial infusion rates for unfractionated heparin in morbidly obese patients. Ann Pharmacother 2010;44:1141-1151 DOI 10.1345/aph.1P088
6. Smith ML, Wheeler KE. Weight-based heparin protocol using antifactor Xa monitoring. Am J Health Syst Pharm 2010;67:371-374.
7. Myzienski AE, Lutz MF, Smythe MA. Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature. Pharmacotherapy 2010;30:105-112.
8. Spruill WJ, Wade WE, Huckaby WG, Leslie RB. Achievement of anti-coagulation by using a weight-based heparin dosing protocol for obese and nonobese patients. Am J Health Syst Pharm 2001;58:2143-2146.
9. Davidson BL, Büller HR, Decousus H, et al.; Matisse Investigators. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost 2007;5:1191-1194.
10. Hurewitz AN, Khan SU, Groth ML, Patrick PA, Brand DA. Dosing of unfractionated heparin in obese patients with venous thromboembolism. J Gen Intern Med 2011;26:487-491.
11. Barletta JF, DeYoung JL, McAllen K, Baker R, Pendleton K. Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity. Surg Obes Relat Dis 2008;4:748-753.
12. Bauer SR, Ou NN, Dreesman BJ, et al. Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study. Mayo Clin Proc 2009;84:1073-1078.
13. Schwiesow SJ, Wessell AM, Steyer TE. Use of a modified dosing weight for heparin therapy in a morbidly obese patient. Ann Pharmacother 2005;39:753-756. DOI 10.1345/aph.1E300
14. Yee WP, Norton LL. Optimal weight base for a weight-based heparin dosing protocol. Am J Health Syst Pharm 1998;55:159-162.
15. Newall F, Johnston L, Ignjatovic V, Monagle P. Unfractionated heparin therapy in infants and children. Pediatrics 2009;123:e510-e518
16. Kim GG, El Rouby S, Thompson J, Gupta A, Williams J, Jobes DR. Monitoring unfractionated heparin in pediatric patients with congenital heart disease having cardiac catheterization or cardiac surgery. J Thromb Thrombolysis 2010;29:429-436.
17. Newall F, Ignjatovic V, Johnston L, et al. Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin. Thromb Haemost 2010;103:1085-1090.
18. Newall F, Ignjatovic V, Johnston L, et al. Clinical use of unfractionated heparin therapy in children: time for change? Br J Haematol 2010;150: 674-678.
19. Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:887S-968S.
20. Khaja WA, Bilen O, Lukner RB, Edwards R, Teruya J. Evaluation of heparin assay for coagulation management in newborns undergoing ECMO. Am J Clin Pathol 2010;134:950-954.